Coming October 29: SITC releases its late-breaking abstract titles. We’ll add their presenting authors’ institutions to this guide once they’re out.

CK Life Sciences at SITC 2026

Nov 4–8, 2026 Phoenix, AZ ~6k attendees Website

CK Life Sciences brings 2 presentations to SITC 2026 in Phoenix. Its program centres on cancer vaccines tested in mouse models, often alongside PD-1 pathway blockade. One vaccine targets both PD-L1 and PRAME, and another uses circular RNA in lipid particles against TROP2, combined with an anti-PD-1 drug.

Organization	SITC 2026 Attendance
CL CK Life Sciences Hong Kong, China
	Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Dual-antigen cancer vaccine co-targeting human PD-L1 and PRAME induces specific immune responses in hPD-1/hPD-L1/HLA-A2.1 mice and inhibits tumor growth in an HLA-A2.1/hPRAME mouse colon cancer model Exhibition Halls 4-6 · Poster 1045 Vaccines Poster Fri Nov 6 12:15–1:45pm 5:30–7pm Enhanced Anti-tumor Efficacy of an hTROP2 circRNA-LNP Vaccine Combined with Anti–PD-1 Therapy in TROP2+ Tumor Models Exhibition Halls 4-6 · Poster 583 Vaccines · New agents

Organization

SITC 2026 Attendance

CK Life Sciences

Hong Kong, China

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Dual-antigen cancer vaccine co-targeting human PD-L1 and PRAME induces specific immune responses in hPD-1/hPD-L1/HLA-A2.1 mice and inhibits tumor growth in an HLA-A2.1/hPRAME mouse colon cancer model

Exhibition Halls 4-6 · Poster 1045

Vaccines

Poster

Fri Nov 6
12:15–1:45pm
5:30–7pm

Enhanced Anti-tumor Efficacy of an hTROP2 circRNA-LNP Vaccine Combined with Anti–PD-1 Therapy in TROP2+ Tumor Models